Soligenix Inc. (NASDAQ:SNGX) Short Interest Update

by · The Markets Daily

Soligenix Inc. (NASDAQ:SNGX – Get Free Report) was the recipient of a large decrease in short interest in June. As of June 15th, there was short interest totaling 479,055 shares, a decrease of 92.6% from the May 31st total of 6,514,042 shares. Approximately 3.3% of the company’s stock are sold short. Based on an average daily volume of 3,609,843 shares, the short-interest ratio is currently 0.1 days.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Soligenix in a report on Tuesday, April 21st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Soligenix presently has an average rating of “Hold” and an average price target of $6.00.

Check Out Our Latest Stock Analysis on SNGX

Institutional Investors Weigh In On Soligenix

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SNGX. XTX Topco Ltd acquired a new position in shares of Soligenix during the 4th quarter worth about $37,000. StoneX Group Inc. bought a new position in shares of Soligenix in the 4th quarter valued at about $50,000. Geode Capital Management LLC increased its position in shares of Soligenix by 88.8% in the fourth quarter. Geode Capital Management LLC now owns 80,401 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 37,811 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Soligenix in the fourth quarter valued at about $51,000. Finally, Banco BTG Pactual S.A. bought a new stake in Soligenix during the third quarter worth about $54,000. 3.60% of the stock is currently owned by institutional investors and hedge funds.

Soligenix Price Performance

Shares of SNGX traded up $0.00 during mid-day trading on Thursday, hitting $0.40. 910,919 shares of the company’s stock were exchanged, compared to its average volume of 3,998,306. The company has a market cap of $5.85 million, a PE ratio of -0.24 and a beta of 1.84. Soligenix has a 52 week low of $0.28 and a 52 week high of $6.23. The company has a 50-day simple moving average of $0.62 and a 200 day simple moving average of $1.04.

Soligenix (NASDAQ:SNGX – Get Free Report) last posted its quarterly earnings data on Friday, May 8th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02. On average, analysts anticipate that Soligenix will post -0.9 earnings per share for the current year.

Soligenix Company Profile

(Get Free Report)

Soligenix, Inc is a clinical‐stage biopharmaceutical company focused on developing vaccines and therapeutics to address unmet medical needs in rare diseases and biodefense. The company leverages proprietary technologies to create novel vaccine adjuvants, small‐molecule innate defense regulators and photodynamic therapies aimed at improving patient outcomes in orphan indications and protecting public health against biological threats.

The company’s pipeline is organized into two core divisions.

Featured Articles